Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Clinical trial NCT05309629 · COMPLETED
Trial details
- NCT number
- NCT05309629
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-18
- Primary completion
- 2023-02-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.